Table 1.

Summary of Key Efficacy Data of Apremilast in Plaque Psoriasis: Results from Phase 3 ESTEEM Trials

Study	Treatment Arm	Number of Patients	PASI-75 Response	sPGA Response
ESTEEM 1	Apremilast 30 mg BID	562	186 (33.1%)	122 (21.7%)
	Placebo	282	15 (5.3%)	11 (3.9%)
	Total	844
ESTEEM 2	Apremilast 30 mg BID	274	79 (28.8%)	56 (20.4%)
	Placebo	137	16 (5.8%)	12 (4.4%)
	Total	411

Abbreviation: BID, twice daily.